Sleijfer Stefan, Kruit Wim H J, Stoter Gerrit
Department of Medical Oncology, Daniel den Hoed Cancer Center, Erasmus University Medical Center, Groene Hilledijk 301, EA Rotterdam 3075, The Netherlands.
Eur J Cancer. 2004 Nov;40(16):2377-82. doi: 10.1016/j.ejca.2004.07.023.
Following reports of its teratogenicity, thalidomide was banned from the market in the 1960s. Later, the elucidation that the inhibition of angiogenesis underlies this teratogenicity and the recognition of the importance of angiogenesis in malignancies has raised interest in thalidomide as an anti-tumour agent. Since then, numerous other mechanisms accounting for the anti-tumour effect of thalidomide have been revealed and many studies exploring the efficacy of thalidomide in tumours have been initiated. This Review focuses on the application of thalidomide and its derivatives in solid tumours, the mechanisms underlying their anti-tumour effects, and their potential to be applied in combination with other anti-tumour agents.
在有关沙利度胺致畸性的报道出现后，它于20世纪60年代被禁止上市。后来，有阐明表明血管生成的抑制是这种致畸性的基础，并且认识到血管生成在恶性肿瘤中的重要性，这引发了人们对沙利度胺作为抗肿瘤药物的兴趣。从那时起，已揭示出许多其他解释沙利度胺抗肿瘤作用的机制，并开展了许多探索沙利度胺在肿瘤中疗效的研究。本综述重点关注沙利度胺及其衍生物在实体瘤中的应用、其抗肿瘤作用的潜在机制以及它们与其他抗肿瘤药物联合应用的潜力。
